Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 17/20 | 0.51 |
| ▸ | CPB1 | P15086 | 10/20 | 0.51 |
| ▸ | CPA1 | P15085 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23376691 | 0.89 | CPB2 (0.47) | CPB2CPB1CPA1CYP2C9TSHR | |
| SCHEMBL24501919 | 0.84 | CPB2 (0.46) | CPB2CPB1CPA1 | |
| SCHEMBL26038341 | 0.82 | CPB2 (0.42) | CPB2CPB1CPA1 | |
| SCHEMBL24501675 | 0.81 | TBXAS1 (0.43) | CPB2CPB1 | |
| SCHEMBL12710071 | 0.79 | KDM5A (0.39) | CPB2CPB1CPA1 | |
| SCHEMBL24496372 | 0.79 | CPB2 (0.40) | CPB2CPB1CPA1CYP2C9TSHR | |
| SCHEMBL20968162 | 0.79 | CPB2 (0.49) | CPB2CPB1 | |
| SCHEMBL24495990 | 0.78 | CPB2 (0.40) | CPB2CPB1CPA1 | |
| SCHEMBL24496206 | 0.78 | CPB2 (0.38) | CPB2CPB1CPA1 | |
| SCHEMBL25581832 | 0.78 | CPB2 (0.54) | CPB2CPB1CPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | SCHERING CORPORATION | 2007-09-13 | — | — | US | disclosed |
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | SCHERING CORPORATION | 2007-09-13 | — | — | US | disclosed |
| WO-2007084498-A1 | PIPERAZINE DERIVATIVES AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | FNTB, FNTA, FDPS | CPB2 1355/4885CPB1 708/4885CPA1 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.